` ELEV (Elevation Oncology Inc) vs S&P 500 Comparison - Alpha Spread

ELEV
vs
S&P 500

Over the past 12 months, ELEV has underperformed S&P 500, delivering a return of -35% compared to the S&P 500's +14% growth.

Stocks Performance
ELEV vs S&P 500

Loading
ELEV
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
ELEV vs S&P 500

Performance Gap Between ELEV and GSPC
HIDDEN
Show

Performance By Year
ELEV vs S&P 500

Loading
ELEV
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Elevation Oncology Inc vs Peers

S&P 500
ELEV
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Elevation Oncology Inc
Glance View

Market Cap
21.6m USD
Industry
Biotechnology

Elevation Oncology, Inc. operates as a precision oncology company. The company is headquartered in New York City, New York and currently employs 35 full-time employees. The company went IPO on 2021-06-25. The firm is focused on the development of targeted therapeutics for the treatment of cancer in genomically-defined patient populations. The company focuses on identifying oncogenic drivers with other driver alterations and in the conduct of clinical trials. Its lead drug development candidate, seribantumab, is an Anti-HER3 monoclonal antibody and potential targeted therapy for solid tumors driven by neuregulin-1 (NRG1) fusions, which are genomic alterations that are identified as oncogenic driver alterations. Its NRG1 is the primary activating ligand of HER3. The firm's clinical trial, CRESTONE, is a Phase II study of seribantumab in cancer patients with a solid tumor of any origin that expresses a genomic change called an NRG1 fusion.

ELEV Intrinsic Value
HIDDEN
Show
Back to Top